Research programme: glycopeptide therapeutics - Opsonic

Drug Profile

Research programme: glycopeptide therapeutics - Opsonic

Latest Information Update: 17 Nov 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Opsonic Therapeutics
  • Class Glycopeptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 24 Oct 2014 RAS® technology is no longer licensed to Opsonic Therapeutics
  • 24 Oct 2014 Discontinued for HIV infections in USA (Parenteral)
  • 21 Apr 2011 Early research is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top